33 results on '"Inzucchi, Silvio E."'
Search Results
2. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.
3. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
4. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
5. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE.
6. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
7. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME.
8. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
9. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
10. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
11. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
12. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.
13. RELATIONSHIP BETWEEN INFLAMMATORY BIOMARKERS AND OUTCOMES: AN ANALYSIS FROM DEFINE-HF.
14. THE EFFECT OF DAPAGLIFLOZIN ON DAYS OF FULL HEALTH LOST DUE TO DEATH, HOSPITALIZATION, AND IMPAIRED WELL-BEING IN DAPA-HF.
15. METABOLIC EFFECTS OF DAPAGLIFLOZIN IN HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION.
16. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL.
17. THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME.
18. DAPAGLIFLOZIN IMPROVES OUTCOMES IRRESPECTIVE OF NT-PROBNP CONCENTRATION IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL.
19. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL.
20. THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER.
21. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION.
22. U.S. PATTERNS OF DRUG UTILIZATION AND PRESCRIPTION FILLS FOR PROVEN CARDIOPROTECTIVE ANTI-HYPERGLYCEMIC AGENTS.
23. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY
24. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
25. Pre-Procedural Glucose Levels and the Risk for Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography
26. The Potential of Myocardial Perfusion Scintigraphy for Risk Stratification of Asymptomatic Patients With Type 2 Diabetes
27. APPLICATION OF THE TIMI HEART FAILURE RISK SCORE TO THE EMPA-REG OUTCOME POPULATION.
28. EFFECT OF TREATMENT WITH DAPAGLIFLOZIN ACCORDING TO BASELINE SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL.
29. EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL.
30. THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME.
31. IN-HOSPITAL HEMOGLOBIN A1C TESTING AND ITS RELATION TO INITIATION OF GLUCOSE LOWERING THERAPY IN HYPERGLYCEMIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
32. TEMPORAL TRENDS IN THE MANAGEMENT OF SEVERE HYPERGLYCEMIA AMONG PATIENTS HOSPITALIZED WITH ACUTE MYOCARDIAL INFARCTION
33. 885-6 Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarction.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.